市場調查報告書
商品編碼
1541023
2024-2032 年按治療類型(連續性門診腹膜透析、自動腹膜透析)、產品、最終用戶和地區分類的腹膜透析市場報告Peritoneal Dialysis Market Report by Treatment Type (Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis ), Product, End User, and Region 2024-2032 |
IMARC Group年全球腹膜透析市場規模達173億美元。
腹膜透析(PD)代表一種腎衰竭治療程序,其中透過手術將軟塑膠管或導管放置在腹壁或腹部。一旦定位,無菌清潔液就會透過管道傳輸,透過清除廢物來幫助過濾人體內的血液。一段時間後,液體和過濾後的不需要的成分從腹部流出並被丟棄。 PD分為連續性非臥床腹膜透析和連續循環腹膜透析(CCPD)。這些方法提供了治療靈活性,減少了前往透析中心的需要,並提供了更好的臨床結果,從而減少了藥物和食物限制。除此之外,它可以在家中進行,而且是無針的;因此,醫院和醫療中心使用 PD 來治療腎衰竭。
高血壓、糖尿病和末期腎病(ESRD)盛行率的不斷上升,腎臟捐贈者的日益短缺,以及消費者對腎臟移植相關風險的認知不斷增強,這些都是市場成長的主要動力。此外,對居家透析治療的需求不斷成長,特別是在 COVID-19 大流行期間,是另一個成長誘導因素。此外,各種技術的出現,例如自動腹膜透析(APD),為患者進行腎臟替代治療和夜間多次交換,都有助於市場成長。這類先進產品有助於降低腹膜炎和疝氣的發生率,並提供更好的小溶質清除率,特別是對於面臨慢性腎臟病 (CKD) 的老年人群。此外,醫療從業者對帕金森氏症的傾向超過了血液透析,因為它可以確保以具有成本效益的價格提高患者流動性,同時減少症狀波動,這正在推動市場成長。除此之外,政府對研發活動(R&D)的廣泛投資、改善報銷政策以及持續的產品多樣化正在積極刺激市場成長。
The global peritoneal dialysis market size reached US$ 17.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.38% during 2024-2032.
Peritoneal dialysis (PD) represents a type of kidney failure treatment procedure wherein a soft plastic tube or catheter is placed in the abdominal lining or belly through surgery. Once it is positioned, a sterile cleansing fluid is transmitted by the duct that helps filter the blood inside an individual's body by removing waste products. After a period of time, the liquid and filtered unwanted components flow out of the abdomen and are discarded. PD is differentiated into continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis (CCPD). These approaches offer treatment flexibility, reduce the need to visit dialysis centers, and provide better clinical outcomes, resulting in lesser medications and fewer food restrictions. Apart from this, it can be carried out at home and is needle-free; thus, PD is used by hospitals and healthcare centers to treat kidney failures.
The increasing prevalence of hypertension, diabetes, and end-stage renal disease (ESRD), the rising shortages of kidney donors, and the emerging awareness amongst consumers regarding the risks associated with kidney transplants are majorly driving the market growth. Moreover, the growing need for home dialysis treatments, especially during the COVID-19 pandemic, is acting as another growth-inducing factor. Furthermore, the advent of various technologies, such as automated peritoneal dialysis (APD), to perform renal replacement therapy for patients and multiple exchanges at night is contributing to the market growth. Such advanced products aid in lowering the incidences of peritonitis and hernias and offer better small solute clearances, especially to the geriatric population facing chronic kidney disease (CKD). Additionally, the shifting inclination of health practitioners toward PD over haemodialysis as it ensures greater patient mobility at cost-effective prices while creating fewer symptom fluctuations is propelling the market growth. Apart from this, extensive investments in research and development activities (R&D) by governments, improving reimbursement policies, and the ongoing product diversification are positively stimulating the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global peritoneal dialysis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on treatment type, product and end user.
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Automated Peritoneal Dialysis (APD)
Peritoneal Dialysis Solution
Peritoneal Dialysis Devices
Peritoneal Dialysis Sets
Peritoneal Dialysis Catheters
Others
Home-based Dialysis
Dialysis Centers and Hospital-based Dialysis
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amecath, Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Medical Components Inc., Medionics International Inc., Medtronic plc, Merit Medical Systems Inc., Mitra Industries Pvt. Ltd., Newsol Technologies Inc., Nipro Canada (Nipro Medical Corporation), Poly Medicure Limited, Terumo Corporation and Utah Medical Products Inc.